Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-02 4:49 pm Purchase |
2025-03-26 | 13G | Surrozen, Inc. SRZN |
Venrock Healthcare Capital Partners III L.P. | 872,546 9.900% |
872,546 (New Position) |
Filing History |
| 2025-02-27 6:43 pm Purchase |
2025-02-10 | 13G | Oruka Therapeutics, Inc. ORKA |
Venrock Healthcare Capital Partners III L.P. | 4,148,428 11.100% |
606,487 (+17.12%) |
Filing History |
| 2025-02-14 6:15 pm Sale |
2024-12-31 | 13G | Mersana Therapeutics, Inc. MRSN |
Venrock Healthcare Capital Partners III L.P. | 10,257,790 8.300% |
-1,070,210 (-9.45%) |
Filing History |
| 2025-02-14 6:15 pm Purchase |
2024-12-31 | 13G | enGene Holdings Inc. Common Stock ENGN |
Venrock Healthcare Capital Partners III L.P. | 5,046,414 9.900% |
1,480,573 (+41.52%) |
Filing History |
| 2025-02-14 6:14 pm Sale |
2024-12-31 | 13G | Century Therapeutics, Inc. IPSC |
Venrock Healthcare Capital Partners III L.P. | 3,957,186 4.700% |
-1,432,073 (-26.57%) |
Filing History |
| 2025-02-14 6:13 pm Sale |
2024-12-31 | 13G | Astria Therapeutics, Inc. ATXS |
Venrock Healthcare Capital Partners III L.P. | 2,457,348 4.400% |
-1,001,297 (-28.95%) |
Filing History |
| 2025-02-14 6:12 pm Sale |
2024-12-31 | 13G | Aquestive Therapeutics, Inc. AQST |
Venrock Healthcare Capital Partners III L.P. | 2,629,786 2.900% |
-2,925,769 (-52.66%) |
Filing History |
| 2025-02-14 6:11 pm Purchase |
2024-12-31 | 13G | Applied Therapeutics, Inc. APLT |
Venrock Healthcare Capital Partners III L.P. | 11,805,301 9.900% |
149,236 (+1.28%) |
Filing History |
| 2025-02-14 6:10 pm Unchanged |
2024-12-31 | 13G | Adverum Biotechnologies, Inc. ADVM |
Venrock Healthcare Capital Partners III L.P. | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2025-02-14 6:09 pm Sale |
2024-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
Venrock Healthcare Capital Partners III L.P. | 2,952,371 6.400% |
-1,447,629 (-32.90%) |
Filing History |
| 2025-02-14 6:08 pm Purchase |
2024-12-31 | 13G | Praxis Precision Medicines, Inc. PRAX |
Venrock Healthcare Capital Partners III L.P. | 1,190,340 6.100% |
283,854 (+31.31%) |
Filing History |
| 2025-02-14 6:06 pm Unchanged |
2024-12-31 | 13G | Spyre Therapeutics, Inc. SYRE |
Venrock Healthcare Capital Partners III L.P. | 2,685,448 4.600% |
0 (Unchanged) |
Filing History |
| 2025-02-14 6:05 pm Unchanged |
2024-12-31 | 13G | Viridian Therapeutics, Inc. VRDN |
Venrock Healthcare Capital Partners III L.P. | 3,575,309 4.500% |
0 (Unchanged) |
Filing History |
| 2025-02-03 7:43 pm Purchase |
2025-01-30 | 13G | Applied Therapeutics, Inc. APLT |
Venrock Healthcare Capital Partners III L.P. | 5,012,796 10.100% |
5,012,796 (New Position) |
Filing History |
| 2024-12-04 4:15 pm Purchase |
2024-11-26 | 13G | Cidara Therapeutics, Inc. CDTX |
Venrock Healthcare Capital Partners III L.P. | 1,129,097 9.990% |
1,129,097 (New Position) |
Filing History |
| 2024-11-14 5:52 pm Purchase |
2024-09-30 | 13G | Zura Bio Limited ZURA |
Venrock Healthcare Capital Partners III L.P. | 6,853,600 9.990% |
453,981 (+7.09%) |
Filing History |
| 2024-11-14 5:52 pm Sale |
2024-09-30 | 13G | Viridian Therapeutics, Inc. VRDN |
Venrock Healthcare Capital Partners III L.P. | 3,575,309 5.500% |
-1,980,259 (-35.64%) |
Filing History |
| 2024-11-14 5:51 pm Sale |
2024-09-30 | 13G | Terns Pharmaceuticals, Inc. TERN |
Venrock Healthcare Capital Partners III L.P. | 3,516,889 4.990% |
-980,228 (-21.80%) |
Filing History |
| 2024-11-14 5:51 pm Sale |
2024-09-30 | 13G | Taysha Gene Therapies, Inc. TSHA |
Venrock Healthcare Capital Partners III L.P. | 9,000,000 4.400% |
-1,412,872 (-13.57%) |
Filing History |
| 2024-11-14 5:50 pm Sale |
2024-09-30 | 13G | Spyre Therapeutics, Inc. SYRE |
Venrock Healthcare Capital Partners III L.P. | 2,685,448 5.300% |
-1,049,066 (-28.09%) |
Filing History |